drugset / Trial / NCT00485459

Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD

NCT00485459

Phase 3 Completed 106 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this protocol is to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy in Taiwanese children and adolescents with ADHD.

Timeline

Start
2004-02
Primary completion
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified